Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy - Preliminary results

European Journal of Gynaecological Oncology

Volumn 26, Issue 4, 2005, Pages 423-426

  Bidzinski M ^a   Danska Bidzinska A ^a   Ziolkowska Seta I ^a   Derlatka, P ^a   Sobiczewski, P ^a   Raczynski P ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

Interval debulking surgery; Neoadjuvant chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE COMPLICATION; SIDE EFFECT; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PACLITAXEL; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 23744440967     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Didkowska J., Wojciechowska U., Tarkowski W., Zatonski W.: "Cancer in Poland in 2000. Polish National Cancer Registry. Department of Epidemiology and Cancer Prevention. The Maria Sklodowska-Curie Memorial Cancer Center". Warsaw 2002.
2. Heintz A.P., Hacker N.F., Berek J.S. et al: "Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity". Obstet. Gynecol., 1986, 67, 783.
3. Hoskins W.J., Bundy B.N., Thigpen J.T. et al.: "The influence of cytoreductive surgery on recurrence-free interval and survival in small volume Stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study". Gynecol. Oncol., 1992, 47, 159.
4. van der Burg M.E., van Lent M., Buyse M. et al.: "The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer". N. Engl. J. Med., 1995, 332, 629.
5. Look M., Chang D., Sugarbaker P.H.: "Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum". Int. J. Gynecol. Cancer, 2004, 14, 35.
6. Bristow R.E., Tomacruz R.S., Armstrong D.K. et al.: "Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era A meta analysis". J. Clin. Oncol., 2002, 20, 1248.
7. Brockbank E.C., Ind T.E.J., Barton D.P.J. et al.: "Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer". Int. J. Gynecol. Cancer, 2004, 14, 42.
8. Lawton F.G., Redman C.W., Luesley D.M., Chan K.K., Blackledge G.: "Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer". Obstet. Gynecol., 1989, 73, 61.
9. Jacob J.H., Gershenson D.M., Morris M., Copeland L.J., Bruke T.W., Wharton J.T.: "Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer". Gynecol. Oncol., 1991, 42, 146.
10. Surwit E., Childers J., Atlas I. et al.: "Neoadjuvant chemotherapy for advanced ovarian cancer". Int. J. Gynecol. Cancer, 1996, 17, 393.
11. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., Thiel R.P.: "Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival". Gynecol. Oncol., 1999, 72, 93.
12. Morice P., Dubernard G., Rey A. et al.: "Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer". J. Am. Coll. Surg., 2003, 197, 955.
13. Kuhn W., Rutke S., Späthe K. et al.: "Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIc ovarian carcinoma". Cancer, 2001, 92, 2585.
14. Allen D.G., Coulter J.: "Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease". Aust., N.Z.J. Obstet. Gynecol., 1999, 39, 420.
15. Di Re E, Baiocchi G, Fontanelli R. et al.: "Systematic pelvic and paraaortic limphadenectomy for advanced ovarian cancer: prognostic significance of node metastases". Gynecol. Oncol., 1996, 62, 360.
16. McGuire W.P., Hoskins W.J., Brady M.F. et al.: "Cyclophosphamide and cisplatine compared with paclitaxel and cisplatin in patients with stage III and Stage IV ovarian cancer". N. Engl. J. Med., 1996, 334, 1.
17. Piccard M.J., Bertelsen K., James K. et al.: "Randomized intergroup trial of cisplatin - paclitaxel versus cisplatin - cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results". J. Natl. Cancer Inst., 2000, 92, 699.